<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Prahalad P</submitter><funding>NIDDK NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>e10023</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC2850308</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(4)</volume><pubmed_abstract>Tumor development, growth, and metastasis depend on the provision of an adequate vascular supply. This can be due to regulated angiogenesis, recruitment of circulating endothelial progenitors, and/or vascular transdifferentiation. Our previous studies showed that retinoic acid (RA) treatment converts a subset of breast cancer cells into cells with significant endothelial genotypic and phenotypic elements including marked induction of VE-cadherin, which was responsible for some but not all morphological changes. The present study demonstrates that of the endothelial-related genes induced by RA treatment, only a few were affected by knockdown of VE-cadherin, ruling it out as a regulator of the RA-induced endothelial genotypic switch. In contrast, knockdown of the RA-induced gene COUP-TFII prevented the formation of networks in Matrigel but had no effect on VE-cadherin induction or cell fusion. Two pan-kinase inhibitors markedly blocked RA-induced VE-cadherin expression and cell fusion. However, RA treatment resulted in a marked and broad reduction in tyrosine kinase activity. Several genes in the TGFbeta signaling pathway were induced by RA, and specific inhibition of the TGFbeta type I receptor blocked both RA-induced VE-cadherin expression and cell fusion. Together these data indicate a role for the TGFbeta pathway and COUP-TFII in mediating the endothelial transdifferentiating properties of RA.</pubmed_abstract><journal>PloS one</journal><pubmed_title>Retinoic acid mediates regulation of network formation by COUP-TFII and VE-cadherin expression by TGFbeta receptor kinase in breast cancer cells.</pubmed_title><pmcid>PMC2850308</pmcid><funding_grant_id>P30 CA51008</funding_grant_id><funding_grant_id>P30 CA051008</funding_grant_id><funding_grant_id>R01 DK058196</funding_grant_id><funding_grant_id>R01 DK58196</funding_grant_id><funding_grant_id>R01 CA129813</funding_grant_id><funding_grant_id>1R01CA129813</funding_grant_id><pubmed_authors>Byers SW</pubmed_authors><pubmed_authors>Ressom H</pubmed_authors><pubmed_authors>Dakshanamurthy S</pubmed_authors><pubmed_authors>Prahalad P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Retinoic acid mediates regulation of network formation by COUP-TFII and VE-cadherin expression by TGFbeta receptor kinase in breast cancer cells.</name><description>Tumor development, growth, and metastasis depend on the provision of an adequate vascular supply. This can be due to regulated angiogenesis, recruitment of circulating endothelial progenitors, and/or vascular transdifferentiation. Our previous studies showed that retinoic acid (RA) treatment converts a subset of breast cancer cells into cells with significant endothelial genotypic and phenotypic elements including marked induction of VE-cadherin, which was responsible for some but not all morphological changes. The present study demonstrates that of the endothelial-related genes induced by RA treatment, only a few were affected by knockdown of VE-cadherin, ruling it out as a regulator of the RA-induced endothelial genotypic switch. In contrast, knockdown of the RA-induced gene COUP-TFII prevented the formation of networks in Matrigel but had no effect on VE-cadherin induction or cell fusion. Two pan-kinase inhibitors markedly blocked RA-induced VE-cadherin expression and cell fusion. However, RA treatment resulted in a marked and broad reduction in tyrosine kinase activity. Several genes in the TGFbeta signaling pathway were induced by RA, and specific inhibition of the TGFbeta type I receptor blocked both RA-induced VE-cadherin expression and cell fusion. Together these data indicate a role for the TGFbeta pathway and COUP-TFII in mediating the endothelial transdifferentiating properties of RA.</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Apr</publication><modification>2024-11-20T05:01:43.703Z</modification><creation>2019-03-26T23:07:27Z</creation></dates><accession>S-EPMC2850308</accession><cross_references><pubmed>20386594</pubmed><doi>10.1371/journal.pone.0010023</doi></cross_references></HashMap>